Related Experiment Video
Updated: Apr 2, 2026

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
Engineered phage-derived lysins effectively kill mycobacterial pathogens
Adel Abouhmad1, Jana Kassaliete2, Camilla Davids2
1Division of Biotechnology, Department of Chemistry, Kemicentrum, Lund University, Box 124, Lund SE-221 00, Sweden; Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Abstract:
Antimicrobial resistance in pathogenic mycobacteria remains a critical challenge due to poor drug penetration through their complex cell wall, which necessitates prolonged multidrug regimens. Mycobacteriophages encode a lytic machinery that can disrupt this barrier. In this research article, we describe a modular mycolysin platform combining phage enzymes Lysin A and Lysin B with outer membrane-permeabilizing peptides and protein transduction domains using VersaTile shuffling technology. Screening the chimeric libraries against Mycobacterium smegmatis and Mycobacterium bovis Bacillus Calmette-Guérin (BCG), followed by the evaluation of selected mycolysin hits, identified potent candidates with minimum inhibitory concentration values as low as 1.28 μg/ml against M. bovis BCG and up to 75 μg/ml against pathogenic nontuberculous mycobacterium Mycobacterium avium. The three most potent mycolysins showed intracellular efficacy, serum stability, noncytotoxicity, in vivo proof-of-concept efficacy in rat wound and pulmonary infection models, and synergy with rifampicin treatment. This biotechnology framework illustrates the promise of translating phage enzymes into next-generation antimycobacterial therapies.
Insights
Researchers developed a novel mycolysin platform using phage enzymes to overcome mycobacterial cell wall barriers. This approach shows promise for developing next-generation antimycobacterial therapies against resistant strains.
Area of Science:
- Biotechnology
- Microbiology
- Drug Discovery
Background:
- Antimicrobial resistance in mycobacteria is a significant global health threat.
- The complex mycobacterial cell wall impedes drug penetration, requiring lengthy treatments.
- Mycobacteriophages possess enzymes capable of degrading the mycobacterial cell wall.
Purpose of the Study:
- To engineer a modular mycolysin platform combining phage enzymes with cell-penetrating moieties.
- To screen and identify potent mycolysin candidates against pathogenic mycobacteria.
- To evaluate the efficacy and safety of lead mycolysin candidates.
Main Methods:
- Utilized VersaTile shuffling technology to create chimeric mycolysin libraries.
- Screened libraries against Mycobacterium smegmatis and Mycobacterium bovis Bacillus Calmette-Guérin (BCG).
- Assessed minimum inhibitory concentrations (MICs), intracellular efficacy, serum stability, cytotoxicity, and in vivo efficacy.
Main Results:
- Identified potent mycolysin candidates with MICs as low as 1.28 μg/ml against M. bovis BCG.
- Demonstrated intracellular efficacy, serum stability, and noncytotoxicity of lead compounds.
- Showcased in vivo proof-of-concept efficacy in rat models and synergy with rifampicin.
Conclusions:
- The developed mycolysin platform effectively targets mycobacterial cell walls.
- These phage-derived enzymes represent a promising strategy for next-generation antimycobacterial therapies.
- The modular platform offers a versatile framework for engineering novel antimicrobials.
Related Concept Videos
Lytic Cycle of Bacteriophages
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Biological Methods for Microbial Control
Lysogenic Cycle of Bacteriophages
DNA Bacteriophages
Inhibitors of Gram-positive Cell Wall Synthesis

